Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Aug 25;15:6409–6420. doi: 10.2147/IJN.S246659

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Peng et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Effects of MP-PTX in tumor proliferation and angiogenesis. (A) Ki-67 (200×) and CD31 (400×) immunohistochemistry in tumor tissue from control, MP, PTX and MP-PTX-treated mice. (B) Quantitative analysis of Ki-67 expression in tumors from control, MP, PTX and MP-PTX treated mice, PTX group and MP-PTX group showed lower number of Ki-67 positive cells compare to control group. MP-PTX effectively inhibit tumor proliferation compared to PTX alone. (C) Quantitative analysis of CD31 expression in tumors from control, MP, PTX and MP-PTX treated mice, PTX group and MP-PTX group showed smaller number of CD31 positive-neovascularized capillaries compare to control group. MP-PTX has a similar effect as PTX in inhibiting tumor microvessel formation (*P < 0.05, **p < 0.01).